The true cost of pharmacological disease prevention

BMJ

Volumn 342, Issue 7805, 2011, Pages

  Järvinen, Teppo L N ^a,b   Sievänen, Harri ^c   Kannus, Pekka ^d   Jokihaara, Jarkko ^e   Khan, Karim M ^e  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b CENTRAL FINLAND CENTRAL HOSPITAL   (Finland)

^c UKK INSTITUTE FOR HEALTH PROMOTION RESEARCH   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL PRACTICE; COMORBIDITY; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIAGNOSTIC ACCURACY; DRUG COST; DRUG EFFICACY; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH SERVICE; HIP FRACTURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR;

COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; PHARMACEUTICAL PREPARATIONS; PREVENTIVE MEDICINE;

EID: 84858999591     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d2175     Document Type: Review

References (21)

1. Relton C, Torgerson D, O'Cathain A, Nicholl J. Rethinking pragmatic randomised controlled trials: introducing the "cohort multiple randomised controlled trial" design. BMJ 2010;340:c1066.
2. van Staa TP, Leufkens HG, Zhang B, Smeeth L. A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example. PLoS Med 2009;6:e1000194.
3. Haynes B. Can it work? Does it work? Is it worth it? The testing of healthcare interventions is evolving. BMJ 1999;319:652-3.
4. Compston JE, Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet 2006;368:973-4. (Pubitemid 44353676)
5. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728-40.
6. Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV, et al. The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 2010;21:495-505.
7. Cooper A, Nherera L, Calvert N, O'Flynn N, Turnbull N, Robson J, et al. Clinical guidelines and evidence review for lipid modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. National Collaborating Centre for Primary Care, Royal College of General Practitioners, 2008.
8. National Institute for Health and Clinical Excellence: Management of hypertension in adults in primary care. NICE clinical guideline 34. NICE, 2006.
9. National Institute for Health and Clinical Excellence: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended). NICE technology appraisal guidance 160. NICE, 2010.
10. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9. (Pubitemid 26147662)
11. Kuehn BM. New tool measures 10-year fracture risk. JAMA 2008;299:1651-2. (Pubitemid 351519882)
12. Järvinen TL, Sievänen H, Khan KM, Heinonen A, Kannus P. Shifting the focus in fracture prevention from osteoporosis to falls. BMJ 2008;336:124-6. (Pubitemid 351211962)
13. Inderjeeth CA, Foo AC, Lai MM, Glendenning P. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence. Bone 2009;44:744-51.
14. Parikh S, Avorn J, Solomon DH. Pharmacological management of osteoporosis in nursing home populations: a systematic review. J Am Geriatr Soc 2009;57:327-34.
15. Sawka AM, Ismaila N, Cranney A, Thabane L, Kastner M, Gafni A, et al. A scoping review of strategies for the prevention of hip fracture in elderly nursing home residents. PLoS One 2010;5:e9515.
16. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-33. (Pubitemid 44607392)
17. Kannus P, Niemi S, Parkkari J, Palvanen M, Vuori I, Järvinen M. Nationwide decline in incidence of hip fracture. J Bone Miner Res 2006;21:1836-8. (Pubitemid 44851558)
18. Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 2003;18:1947-54. (Pubitemid 37377443)
19. Dawson J, Doll H, Fitzpatrick R, Jenkinson C, Carr AJ. The routine use of patient reported outcome measures in healthcare settings. BMJ 2010;340:c186.
20. Robertson MC, Gardner MM, Devlin N, McGee R, Campbell AJ. Effectiveness and economic evaluation of a nurse delivered home exercise programme to prevent falls. Part 2: controlled trial in multiple centres. BMJ 2001;322:701-4. (Pubitemid 32238774)
21. Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med 2009;151:203-5.